Skip to content
Doptelet(avatrombopag)
Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Doptelet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avatrombopag maleate
Tradename
Company
Number
Date
Products
DOPTELETAkaRxN-210238 RX2018-05-21
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dopteletNew Drug Application2020-10-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
thrombocytopeniaHP_0001873D013921D69.6
Agency Specific
FDA
EMA
Expiration
Code
AVATROMBOPAG MALEATE, DOPTELET, AKARX INC
2026-06-26ODE-246
2023-05-21NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Avatrombopag Maleate, Doptelet, Akarx Inc
76385362025-05-05DS, DP
83384292023-06-30U-2577
87657642023-01-15U-2314, U-2578
ATC Codes
B: Blood and blood forming organ drugs
— B02: Antihemorrhagics
— B02B: Vitamin k and other hemostatics
— B02BX: Other systemic hemostatics in atc
— B02BX08: Avatrombopag
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.63644320
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.34252215
Liver cirrhosisD008103EFO_0001422K74.0———1—1
Liver failureD017093HP_0001399K72.9———1—1
FibrosisD005355———1—1
Connective tissue diseasesD003240EFO_1001986M35———1—1
Chronic hepatitis bD019694EFO_0004197B18.1———1—1
Acute-on-chronic liver failureD065290———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aplastic anemiaD000741HP_0001915D61.9—21—35
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.9—1———1
Liver diseasesD008107EFO_0001421K70-K77—1———1
NeoplasmsD009369C80—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAVATROMBOPAG
INNavatrombopag
Description
Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.
Classification
Small molecule
Drug classthrombopoetin agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1
Identifiers
PDB—
CAS-ID570406-98-3
RxCUI—
ChEMBL IDCHEMBL2103883
ChEBI ID—
PubChem CID9852519
DrugBankDB11995
UNII ID3H8GSZ4SQL (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MPL
MPL
Organism
Homo sapiens
Gene name
MPL
Gene synonyms
TPOR
NCBI Gene ID
4352
Protein name
thrombopoietin receptor
Protein synonyms
CD110, Myeloproliferative leukemia protein, myeloproliferative leukemia virus oncogene, Proto-oncogene c-Mpl, TPO-R
Uniprot ID
Q5JUZ0
Mouse ortholog
Mpl (17480)
thrombopoietin receptor (Q08351)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 287 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,349 adverse events reported
View more details